NASDAQ:TLSA Tiziana Life Sciences (TLSA) Stock Price, News & Analysis $0.99 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.93▼$1.0750-Day Range$0.72▼$1.0152-Week Range$0.41▼$1.10Volume170,146 shsAverage Volume169,950 shsMarket Capitalization$102.06 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesOptions ChainSEC FilingsShort InterestTrends Get Tiziana Life Sciences alerts: Email Address Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Tiziana Life Sciences Stock (NASDAQ:TLSA)Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.Read More TLSA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TLSA Stock News HeadlinesJuly 25 at 10:57 PM | finanznachrichten.deTiziana Life Sciences Ltd.: Tiziana Life Sciences Granted FDA Fast Track DesignationJuly 24 at 9:40 AM | proactiveinvestors.comTiziana Life Sciences secures FDA Fast Track status for MS therapy intranasal foralumabJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…July 24 at 7:00 AM | globenewswire.comTiziana Life Sciences Granted FDA Fast Track DesignationJune 28, 2024 | proactiveinvestors.comTiziana Life Sciences secures $3.4M in non-dilutive fundingJune 28, 2024 | globenewswire.comTiziana Receives $3.4 Million in Non-Dilutive FundingJune 26, 2024 | proactiveinvestors.comTiziana Life Sciences secures FDA approval to dose first patient with moderate Alzheimer's with investigational therapyJune 26, 2024 | globenewswire.comTiziana Life Sciences to Dose First Patient with Moderate Alzheimer's Disease with ForalumabJuly 27, 2024 | Crypto 101 Media (Ad)Next opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has led to a massive bull run in the year after it happens. That means we're in the "golden window" right now…June 11, 2024 | proactiveinvestors.comTiziana Life Sciences seeks FDA Fast Track Designation for foralumab in MS treatmentJune 6, 2024 | proactiveinvestors.comTiziana Life Sciences reports qualitative improvement in MS patients treated with lead assetJune 4, 2024 | proactiveinvestors.comTiziana Life Sciences seeks funding from ALS Association for intranasal foralumab trialMay 30, 2024 | globenewswire.comTiziana Life Sciences Scientific Board Chairman to Receive Prestigious Award for Multiple Sclerosis ResearchMay 13, 2024 | proactiveinvestors.comTiziana eyes orphan drug designation for multiple sclerosis treatmentMay 13, 2024 | globenewswire.comTiziana Life Sciences Files for Orphan Drug Designation for Intranasal ForalumabMay 3, 2024 | morningstar.comTiziana Life Sciences Ltd Ordinary Shares TLSAApril 25, 2024 | proactiveinvestors.comTiziana Life Sciences unveils positive neuroimaging data for foralumab in MS patientsApril 25, 2024 | globenewswire.comTiziana Life Sciences Reports Positive 3-Month Neuroimaging Scores in Multiple Sclerosis Patients Receiving Intranasal ForalumabSee More Headlines Receive TLSA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tiziana Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today7/26/2024Next Earnings (Estimated)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TLSA CUSIPN/A CIK1723069 Webwww.tizianalifesciences.com Phone44-20-7495-2379FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio1.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.05 per share Price / Book19.80Miscellaneous Outstanding Shares103,090,000Free Float62,038,000Market Cap$102.06 million OptionableOptionable Beta0.66 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Gabriele Marco Antonio Cerrone M.B.A. (Age 52)Founder, Executive Chairman & Interim CEO Comp: $817kMs. Keeren Shah (Age 48)Chief Financial Officer Dr. Matthew W. Davis M.D.R.Ph., COO & Chief Medical OfficerDr. William A. Clementi Ph.D.Pharm.D., Chief Development OfficerDr. Napoleone Ferrara M.D. (Age 66)Member of Scientific Advisory Board Key CompetitorsVanda PharmaceuticalsNASDAQ:VNDAAC ImmuneNASDAQ:ACIUInozyme PharmaNASDAQ:INZYALX OncologyNASDAQ:ALXONkartaNASDAQ:NKTXView All Competitors TLSA Stock Analysis - Frequently Asked Questions How have TLSA shares performed this year? Tiziana Life Sciences' stock was trading at $0.56 at the beginning of 2024. Since then, TLSA stock has increased by 76.8% and is now trading at $0.99. View the best growth stocks for 2024 here. When did Tiziana Life Sciences IPO? Tiziana Life Sciences (TLSA) raised $10 million in an initial public offering on the week of November 19th 2018. The company issued 1,000,000 shares at $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO. How do I buy shares of Tiziana Life Sciences? Shares of TLSA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Tiziana Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tiziana Life Sciences investors own include Pfizer (PFE), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Moderna (MRNA) and Enterprise Products Partners (EPD). This page (NASDAQ:TLSA) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tiziana Life Sciences Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Tiziana Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.